Development
Lantern Pharma Inc.
LTRN
$3.32
-$0.11-3.21%
NASDAQ
| 09/30/2023 | 06/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -19.51% | -5.84% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -32.11% | 21.09% | |||
| Operating Income | 32.11% | -21.09% | |||
| Income Before Tax | 33.39% | -22.72% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 33.39% | -22.72% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 33.39% | -22.72% | |||
| EBIT | 32.11% | -21.09% | |||
| EBITDA | 32.14% | -21.10% | |||
| EPS Basic | 33.39% | -22.74% | |||
| Normalized Basic EPS | 33.38% | -22.68% | |||
| EPS Diluted | 33.39% | -22.74% | |||
| Normalized Diluted EPS | 33.38% | -22.68% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||